MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s Disease: An in vivo [11C]BU99008 PET study

H. Wilson, G. Dervenoulas, G. Pagano, R. Tyacke, J. Myers, R. Gunn, E. Rabiner, D. Nutt, M. Politis (London, United Kingdom)

Meeting: 2019 International Congress

Abstract Number: 1985

Keywords: Inflammation, Parkinsonism, Positron emission tomography(PET)

Session Information

Date: Wednesday, September 25, 2019

Session Title: Neuroimaging

Session Time: 1:15pm-2:45pm

Location: Les Muses Terrace, Level 3

Objective: We aimed to evaluate the role of astroglia activation in Parkinson’s disease (PD) using [11C]BU99008 PET, a novel radioligand with high specificity and selectivity for imidazoline 2 binding sites (I2BS).

Background: In PD, astroglia cells display α-synuclein-positive accumulations in the cytoplasm and may play a role in disease initiation and progression. The imidazoline 2 binding sites (I2BS) are expressed on activated astrocytes; therefore, by measuring I2BS levels we can indirectly evaluate astrogliosis in PD.

Method: Twenty-two patients with PD, 8 early and 14 moderate/advanced, and 14 healthy controls (HCs) underwent MRI and [11C]BU9908 PET corrected with arterial input function. Regional volume of distribution (VT) was calculated using the two-tissue compartment model with MIAKAT.

Results: In early PD, increased [11C]BU99008 VT was observed in frontal, temporal, parietal and occipital cortical regions (P<0.05), with the greatest increase in the brainstem (P=0.018), compared to HCs. In moderate/advanced PD, loss of [11C]BU99008 VT uptake was observed across frontal, temporal, parietal, occipital, insula cortices, and the caudate, putamen, thalamus and brainstem (P<0.05). Loss of [11C]BU99008 VT in frontal (r=-0.61), temporal (r=-0.61), parietal (r=-0.59), occipital (r=0.58), insula (r=-0.60) cortices, and the caudate (r=-0.63), putamen (r=-0.620), thalamus (r=-0.61) and brainstem (r=-0.56) correlated with longer disease duration (P<0.05). In the subgroup of moderate/advanced Parkinson’s patients, loss of [11C]BU99008 VT in the frontal (r=0.78), temporal (r=0.735) and parietal (r=0.79) cortex correlated with global cognitive impairment (P<0.05).

Conclusion: This study demonstrates in vivo the role of astroglia in the initiation and progression of Parkinson’s disease. Astrogliosis observed early in Parkinson’s disease could reflect a neuroprotective compensatory mechanisms and pro-inflammatory upregulation in response to α-synuclein accumulation. However, as the disease progresses and significant neurodegeneration occurs, astroglia lose their reactive function and such loss in the cortex has clinical relevance in the development of cognitive impairment.

To cite this abstract in AMA style:

H. Wilson, G. Dervenoulas, G. Pagano, R. Tyacke, J. Myers, R. Gunn, E. Rabiner, D. Nutt, M. Politis. Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s Disease: An in vivo [11C]BU99008 PET study [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/evaluation-of-imidazoline-2-binding-sites-reflecting-astroglia-pathology-in-parkinsons-disease-an-in-vivo-11cbu99008-pet-study/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/evaluation-of-imidazoline-2-binding-sites-reflecting-astroglia-pathology-in-parkinsons-disease-an-in-vivo-11cbu99008-pet-study/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley